Thiruvanantha Puram Today

Biliary Tract Cancer Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Merck, AstraZeneca, Zymeworks & BeiGene, Taiho Oncology

 Breaking News
  • No posts were found

Biliary Tract Cancer Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Merck, AstraZeneca, Zymeworks & BeiGene, Taiho Oncology

March 10
06:52 2023
Biliary Tract Cancer Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Merck, AstraZeneca, Zymeworks & BeiGene, Taiho Oncology
The Biliary Tract Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Tract Cancer pipeline products will significantly revolutionize the Biliary Tract Cancer market dynamics.

DelveInsight’s “Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Biliary Tract Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Biliary Tract Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Tract Cancer Market Insights

 

Biliary Tract Cancer Overview

The common malignant hepatic lesions include hepatocellular carcinoma (HCC), Biliary Tract Cancer (BTC), and other metastatic diseases. Biliary tract cancer (BTC) constitute epithelial malignancies of the biliary tree and include the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). CCA is further divided into intra-hepatic CCA, perihilar (Klatskin’s tumor), and distal CCA.

 

Some of the key facts of the Biliary Tract Cancer Market Report: 

  • The Biliary Tract Cancer market size was valued approximately USD 530 Million in the year 2021 is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In the year 2021, the total incident cases of Biliary Tract Cancer was found to be 37,451 in the 7MM. The most number of Biliary Tract Cancer cancer cases were found in Japan followed by the United States
  • The total incident cases of Biliary Tract Cancer were found to be 14,218, and 10,317 in the year 2021 in Japan and the United States
  • The total stage-specific cases of Biliary Tract Cancer were found to be 2,631, 1,960, 1,909, and 3,817 cases for Stage I, Stage II, Stage III, and Stage IV patients in the United States
  • Key Biliary Tract Cancer Companies: Merck, AstraZeneca, Zymeworks & BeiGene, Taiho Oncology, Eisai, TransThera Sciences, Basilea Pharmaceuticals, Eisai and Merck, Delcath Systems, and others
  • Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Zanidatamab, Futibatinib (TAS-120), Melphalan, Tasugratinib (E7090), TT-00420, Derazantinib (ARQ-087), Lenvima (lenvatinib), and others

 

Get a Free sample for the Biliary Tract Cancer Market Report – 

https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market

 

Key benefits of the Biliary Tract Cancer Market report:

  1. Biliary Tract Cancer market report covers a descriptive overview and comprehensive insight of the Biliary Tract Cancer Epidemiology and Biliary Tract Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Biliary Tract Cancer market report provides insights on the current and emerging therapies.
  3. Biliary Tract Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Biliary Tract Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Biliary Tract Cancer market.

 

Download the report to understand which factors are driving Biliary Tract Cancer epidemiology trends @ Biliary Tract Cancer Epidemiological Insights 

 

Biliary Tract Cancer Market  

The dynamics of the Biliary Tract Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

 

Biliary Tract Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Biliary Tract Cancer Epidemiology Segmentation:

The Biliary Tract Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Biliary Tract Cancer
  • Prevalent Cases of Biliary Tract Cancer by severity
  • Gender-specific Prevalence of Biliary Tract Cancer
  • Diagnosed Cases of Episodic and Chronic Biliary Tract Cancer

 

Biliary Tract Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Tract Cancer market or expected to get launched during the study period. The analysis covers Biliary Tract Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Biliary Tract Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Biliary Tract Cancer market share @ Biliary Tract Cancer market forecast 

 

Biliary Tract Cancer Therapies and Key Companies

  • Keytruda (pembrolizumab): Merck
  • Imfinzi (durvalumab): AstraZeneca
  • Zanidatamab: Zymeworks & BeiGene
  • Futibatinib (TAS-120): Taiho Oncology
  • Melphalan: Delcath Systems
  • Tasugratinib (E7090): Eisai
  • TT-00420: TransThera Sciences
  • Derazantinib (ARQ-087): Basilea Pharmaceuticals
  • Lenvima (lenvatinib): Eisai and Merck

 

Biliary Tract Cancer Market Drivers

  • Identification of novel biomarkers
  • New coding system for CCA
  • Increasing R&D activities

 

Scope of the Biliary Tract Cancer Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Biliary Tract Cancer Companies: Merck, AstraZeneca, Zymeworks & BeiGene, Taiho Oncology, Eisai, TransThera Sciences, Basilea Pharmaceuticals, Eisai and Merck, Delcath Systems, and others
  • Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Zanidatamab, Futibatinib (TAS-120), Melphalan, Tasugratinib (E7090), TT-00420, Derazantinib (ARQ-087), Lenvima (lenvatinib), and others
  • Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
  • Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Biliary Tract Cancer Unmet Needs, KOL’s views, Analyst’s views, Biliary Tract Cancer Market Access and Reimbursement 

 

Biliary Tract Cancer Market Barriers

  • Lack of specific approach
  • Complex and heterogeneous nature of the disease
  • Development of chemo resistance in cholangiocarcinoma

 

Table of Contents 

1. Biliary Tract Cancer Market Report Introduction

2. Executive Summary for Biliary Tract Cancer

3. SWOT analysis of Biliary Tract Cancer

4. Biliary Tract Cancer Patient Share (%) Overview at a Glance

5. Biliary Tract Cancer Market Overview at a Glance

6. Biliary Tract Cancer Disease Background and Overview

7. Biliary Tract Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Biliary Tract Cancer 

9. Biliary Tract Cancer Current Treatment and Medical Practices

10. Biliary Tract Cancer Unmet Needs

11. Biliary Tract Cancer Emerging Therapies

12. Biliary Tract Cancer Market Outlook

13. Country-Wise Biliary Tract Cancer Market Analysis (2019–2032)

14. Biliary Tract Cancer Market Access and Reimbursement of Therapies

15. Biliary Tract Cancer Market Drivers

16. Biliary Tract Cancer Market Barriers

17.  Biliary Tract Cancer Appendix

18. Biliary Tract Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Biliary Tract Cancer treatment, visit @ Biliary Tract Cancer Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis

Related Articles